Get started

Pharmaceuticals

Novartis AG (NOVN.vx) bearish scenario:The technical figure Triangle can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin; production ceased 2020), terbinafine (Lamisil), deferasirox (Exjade), and others. The Triangle has broken through the support line on 03/05/2022, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 12 days towards 80.160 CHF. Your stop loss order according to experts should be placed at 87.480 CHF if you decide to enter this position. Novartis said earnings and sales rose in the first quarter of the year, boosted by its key drugs, including heart failure treatment Entresto. Net income was $2.2 billion, up from $1.8 billion in the same quarter the previous year, on sales that grew to $12.53 billion from $12.41 billion. Analysts expected sales of $12.62 billion. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
SIX:NOVNShort
by legacyFXofficial
2
Sell off in FSD soon to Rebound www.tradingview.com FSD Pharma has been ahead of the bearish behaviors we are beginning to see in heavily weighted areas of the market. On top of that, the entire cannabis sector of the market has been experiencing this type of behavior quite some time way before these big sell offs in fear of inflation rates and interest. Now keep in mind once these sell offs find their bottom, we will see a huge turn around in the buying power and influx of new retail investors and hedge funds. These purchases are going to mainly be going towards what has been UNDERVALUED the LONGEST. which again falls into the cannabis timeline. Not to mention FSD is currently undergoing a buyback on a portion of outstanding shares and is fresh off of a recent acquisition of LUCID, which will be conducting 2 of the 3 main psychopharmaceutical initiatives to apparently be a huge stepping stone in treating certain disorders and neuro- inflammatory diseases of the brain, from anxiety and depression to MS. Not to mention various other autoimmune disorders. I believe there is a very large rebound given my analysis using certain variables from the Hertz wave theory (rev). Potentially another large sell-off and (3rd) breakthrough outside the channel could result in this bear run to finally bottom out and show an increase in value over the next few years, along with their advancements and contributions to the medical and psycho-medicinal community .
HLong
by joekuykendall45
Healthcare is still in a bull market - be longAt the start of 2022, healthcare stocks have gotten killed, especially anything that was a winner in the past 1-2 years. A lot of people are getting rather bearish, but they shouldn't be. The fundamentals favor healthcare still in many ways, and momentum is still rather strong. We already got the breakout in healthcare stocks, and we just got the retest, which was enough to scare a lot of people out. Now is a great entry for a long position, coming out of a short consolidation into a potential new bull phase.
AMEX:XLVLong
by GTStockmaster
MRK has a lot of headline potential from hereHeadline Potential Merck has three drugs currently under priority FDA review, one of them a Covid-19 drug: Molnupiravir, an antiviral for Covid-19 which has received a positive opinion from the advisory board and which Merck's CEO says should work against any variant Vaxneuvance, a pneumococcal vaccine Lynparza, a breast cancer drug Merck also continues to make strong headway with Keytruda, an immunotherapy, which recently picked up another approval in Japan. All of this means that Merck has a lot of headline potential in coming weeks, especially at a time when a new Covid-19 variant is spreading across the world. There's quite a bit of options activity in Merck today as traders place bets ahead of the news. Technicals and Sentiment Merck is currently near support from a long-term trend line and from the 200-day EMA. It has 26% upside to the average analyst price target and a bullish put/call ratio of .43. It has an average analyst rating of 9.3/10, which is very high. It gets an above average ESG score of 2.25/3. Value S&P Global gives Merck's fundamentals an average score of 90/100. IIt's currently trading -1.4 standard deviations below where it usually trades in relation to its major moving averages. Forward dividend yield is about 3.7%, forward P/E just over 11, forward P/S about 3.4. The price to free cash flow ratio is fairly high, at over 20, but that has to be interpreted in light of the other multiples. estimate that Merck has about 18% upside to its average price multiple of the last 3 years. Its earnings outlook is highly positive; I score its growth forecast a 5/6.
NYSE:MRKLong
by ChristopherCarrollSmith
9
VRTX Long Chance on ChannelNASDAQ:VRTX had an ongoing negative Trend since July 2020. It broke the negative Trend 2 days ago. For me its a very good chance and low price for VRTX. strong up move with good volume crossing the negative trend crossed EMA200 and MA200 on daily chart and also on weeky chart still above EMA200 and MA200 on monthly chart still in positive trend since 2008 good position in the market good cashflow for the next years, even if products are failing
NASDAQ:VRTXLong
by JulianRichard11
1